Clonal expansion and specific cytotoxicity of autologous or allogeneic T cells induced by M2a cells

AIM: To investigate clonal expansion and specific cytotoxicity of TCR Vβ subfamily T cells from acute myelogenous leukemia M_2a subtype (AML-M_2a)patients and normal individuals induced by AML-M_2a cells, respectively. METHODS: Complementarity determining region 3(CDR3) of TCR β with variable region genes was amplified in autologous or allogeneic T cells from mixed lymphocyte and tumor culture (MLTC) using RT-PCR. The positive products were further analyzed to identify the clonality of T cells by genescan. The specific cytotoxicity of T cells was analyzed by MTT. RESULTS: T cells from both M_2a patients and normal individuals after MLTC showed high response to M_2a cells with 4-17 TCR Vβ subfamily dominant utilization, one or two clonal expansion of T cells were identified in some predominant TCR Vβ subfamilies. Difference of distribution and clonal expansion of TCR Vβ subfamily T cells were related to source of T cells and the phase during MLTC. Compared with LAK cell, most of T cells from MLTC were CD3⁺CD8⁺T cells with higher and more specific cytoxicity to the induced cells, M_2a cells, but not HL60 or K562 cell line. CONCLUSION: Clonal expansion of TCR Vβ subfamily T cells stimulated selectively by M_2a cells may be a specific immune response of autologous and allogeneic T cells to M_2a cells associated antigen. The T cells induced by M_2a cells have the ability of specific cytoxicity to the AML-M_2a cells.     

The feature of clonal expansion of TCR Vβ T cells from peripheral blood in patients with acute monoblastic leukemia

AIM: To investigate the distribution and clonal expansion of TCR Vβ subfamily T cells in patients with acute monoblastic leukemia (M5). METHODS: The CDR3 of TCR Vβ 24 subfamily genes were amplified in peripheral blood mononuclear cells from 9 cases with M5 using RT-PCR and the PCR products were further labeled with fluorescent and analyzed by genescan technique for the CDR3 size, to evaluate clonality of the detectable TCR Vβ T cells. RESULTS: Only 1-10 Vβ subfamily T cells were identified in M5 cases. Genescan analysis showed that oligoclonal (clonal expansion) T cells were found in some Vβ subfamilies from 8 cases with M5, Vβ 2 oligoclonal T cells were identified in six cases, whereas Vβ 7- or Vβ 9 clonal expansion T cells were detected in the other two cases, respectively. In addition, except Vβ 2, Vβ 7 or Vβ 21 oligoclonal T cells could be detected in two cases, respectively. CONCLUSION: The skew distribution and clonal expansion of TCR Vβ subfamily T cells could be found in patients with M5.It may be a specific ant i-leukemia immune response with which the host T cells were activated by the leukemia-associated-antigen.The clonal expansion T cells were tendentious in Vβ 2,which may be related to the M5 leukemia cells as sociated antigen.     

Analysis of the distribution and clonality of TCR Vβ T cells in cord blood

AIM:To investigate the distribution and clonality of TCR Vβ subfamily T cells in cord blood. METHODS:The CDR3 of TCR Vβ 24 subfamily genes were amplified in mononuclear cells from 13 cases of cord blood. To observe the usage of TCR Vβ repertoire, the PCR products were further labeled with fluorescent and analyzed by genescan technique for the CDR3 size, to evaluate clonality of the detectable TCR Vβ T cells. Peripheral bloods from 10 cases of normal individuals and T cell line Molt-4 and Jurkat served as controls. RESULTS:Only 38.78%±16.26% of 24 Vβ subfamily T cell were selectively expressed in cord blood, predominantly in Vβ 3, 5, 8, 9 and 13, whereas all 24 Vβ subfamilies could be detected in T cells from peripheral blood of normal individuals. Genescan analysis showed that all PCR products of TCR Vβ subfamilies from cord blood or normal individual peripheral blood displayed multi-peaks. CONCLUSION:Some TCR Vβ subfamily T cells were absent in cord blood. All TCR Vβ subfamily T cells in cord blood displayed polyclonality.     

The feature of TCR Vα repertoire and clonal expansion of T cells from peripheral blood in patients with acute monoblastic leukemia

AIM: To investigate the distribution and clonal expansion of 29 T cell receptor (TCR) Vα subfamily T cells in patients with acute monoblastic leukemia (AML-M5)．METHODS: The CDR3 of TCR Vα 29 subfamily genes were amplified in peripheral blood mononuclear cells (PBMCs) from 8 cases with AML-M5 using RT-PCR，and the PCR products were further labeled with fluorescent and analyzed by genescan technique for the CDR3 size,to evaluate clonality of the detectable TCR Vα subfamily T cells.9 normal individuals served as control.RESULTS: Most Vα subfamily genes could be detected in PBMCs from normal individuals,whereas only 1-10 subfamily T cells were identified in 8 cases with AML-M5,the highest frequently expressed Vα subfamily was Vα3 (75%),and Vα12 was the second (62.5%),15 Vα subfamilies (Vα1,4,5,7,9,14-18,20,21,26,28 and Vα29) were absent.Genescan analysis showed that clonal expanded T cells were found in T cells from 6 out of 8 AML-M5 cases.The highest frequency of clonal expanded T cells predominated in Vα12 (3 out of 5 positive samples).In PBMCs from two cases,clonal expanded Vα3 T cells were the unique detectable Vα subfamily T cells.CONCLUSION: The selected usage and clonal expansion of TCR Vα subfamily T cells from peripheral blood could be found in patients with AML-M5.It may be a specific immune response which the host T cells are activated by the M5 leukemia cells.The distribution pattern of Vα subfamily clonal expansion displays individual specificity．     

Restricted expansion of T cell receptor (TCR)Vβ genes in leukemic patients subjected to allogeneic hematopoeitic stem cell transplantation

AIM: To investigate restricted expansion of TCR Vβ gene repertoire in patients with leukemia following allogeneic hematopoietic stem cell transplantation. METHODS: TCR Vβ subfamily genes in peripheral blood mononuclear cells from 7 cases of leukemia was amplified using RT-PCR. RESULTS: Only two-eight fragments of Vβ genes were detected in samples from these patients, and the detected fragments are different in different patients. CONCLUSION: TCR complexes were abnormal in all patients, part of the genes were seletively expansed and part of them were suppressed after transplantation.     

Establishment of method for PD-1 immunophenotype detection in TCR Vβ repertoire of CD3+, CD4+ and CD8+ T-cell subsets

AIM:To establish the method for detecting the immunophenotype of immunosuppressive receptor programmed cell death protein 1 (PD-1) in T-cell receptor (TCR) Vβ repertoire of CD3⁺, CD4⁺ and CD8⁺ T-cell subsets, therefore to evaluate the distribution of PD-1 in T-cell repertoire from human peripheral blood (PB). METHODS:The PB samples from 10 cases of healthy individuals (HI) were collected. Using multi-colored fluorescence flow cytometry, the distribution frequency of PD-1 in TCR Vβ repertoire was detected with a wide panel of anti-CD45, anti-CD3, anti-CD4, anti-CD8, anti-PD-1 and 24 anti-TCR Vβ repertoire (IOTest^® Beta Mark TCR Vβ Repertoire Kit, containing 8 tubes which labeled A~H, each tube is a composite antibody of FITC and PE coupling, each cocktail contains antibodies direc-ted to 3 different Vβ subfamilies) monoclonal antibodies. RESULTS:The total number of the 24 TCR Vβ repertoire detected in CD3⁺, CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells from 10 cases of HI was consistent with the Quick Reference Card data provided by the kit. The preliminary results showed that the frequency of Vβ usage in CD3⁺, CD4⁺ and CD8⁺ T cells was different. High usage of Vβ2, Vβ3, Vβ8, Vβ9, Vβ5.1, Vβ13.1 and Vβ13.2 was found in CD3⁺ T cells, while high usage of Vβ2, Vβ3, Vβ8, Vβ5.1, Vβ9 and Vβ13.1 in CD3⁺CD4⁺ T cells, and high usage of Vβ1, Vβ2, Vβ3, Vβ9, Vβ13.1 and Vβ13.2 in CD3⁺CD8⁺ T cells were also observed. Further analysis showed that the expression of PD-1 was detected in all 24 TCR Vβ subfamilies of CD3⁺, CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells. The higher frequency of PD-1⁺ T cells was CD4⁺Vβ5.2⁺ T cells, whereas the higher frequency of PD1⁺ T cells in CD8⁺Vβ11⁺ and CD8⁺Vβ13.6⁺ T cells was detected. CONCLUSION:The method for detection of the immunosuppressive receptor PD-1 in TCR Vβ repertoire of T-cell subsets is successfully established, which provides a new method for further analysis of immunosuppressive characteristics of TCR Vβ repertoire in the patients with leukemia.     

Expression of TCR Vβ subfamily in patients with idiopathic thrombocytopenic purpura

AIM: To investigate the expression of TCR Vβ subfamily in T cells in patients with idiopathic thrombocytopenic purpura (ITP). METHODS: The TCR Vβ 24 subfamily genes were amplified in peripheral blood mononuclear cells from 5 cases with ITP using RT-PCR, to observe the usage of TCR Vβ repertoire. 10 normal individuals served as controls. RESULTS: Only 4-11 Vβ subfamily in T cells were identified in ITP cases. The frequent expressions of Vβ subfamilies were Vβ2 (100%), Vβ3 (100%), Vβ19 (80%) and Vβ21 (80%), while the expression of Vβ4, Vβ6-12, Vβ17, Vβ20 and Vβ24 were not detected. All 24 Vβ subfamilies were detected in samples from normal individuals. CONCLUSION: The restricted expression of TCR Vβ subfamilies is one of the T-cell immune features in patients with ITP, indicating that it may be related to the disorder of cellular immune function in ITP.     

Specific cytotoxicity of TCR Vα23 - Vβ13 gene-modified T-cells

AIM: To analyze the cytotoxicity of TCR Vα23 - Vβ13 gene-modified T-cells specific to diffuse large B-cell lymphoma(DLBCL) associated antigens in vitro. METHODS: The identified full-length TCR Vβ13 and Vα23 genes of monoclonally expanded T-cells in the peripheral blood from a DLBCL patient were amplified and cloned. The bicistronic recombinant plasmid TCR Vβ13 -IRES-TCR Vα23 was constructed and transfected into T-cells isolated from a healthy individual by Nucleofector^TM technology. The mRNA expression of antigen-specific TCR Vα23 and Vβ13 genes and the corresponding proteins were determined by real-time PCR and Western blotting, respectively. The specific cytotoxicity of TCR gene-transferred T-cells in vitro was detected. RESULTS: The recombinant plasmid was constructed successfully and verified by restriction enzyme digestion and nucleotide sequencing. The co-expression of antigen-specific TCR Vα23 and Vβ13 genes at mRNA and protein levels in the transfected healthy T-cells were observed in vitro. Three days after transfection, the cytotoxicity of TCR gene-transduced CD3⁺T-cells against Toledo cells was significantly higher than that against Raji cells or Molt-4 cells. The DLBCL-specific cytotoxic T-lymphocytes(CTL) were inducted. CONCLUSION: The bicistronic eukaryotic expression plasmid TCR Vβ13 -IRES-TCR Vα23 specific to DLBCL-associated antigens is constructed successfully. The TCR gene-transferred T-cells display the ability of DLBCL-specific cytotoxicity.     

The effect of antisense bcr-abl oligonucleotides on the growth of K562 cells

AIM:To study the effect of bcr- abl gene antisense phosphorothioate oligonucleotides(Aspo) on K562 cell line and explore its significance in chrenic myelogeneous leukemia (CML) gene therapy.METHODS:Cells were exposed to oligomeis, observed by inverted microscope.Cells inhibitory rate were determined by 0.4 trypan blue exclusion . CFU-K562 were cultured in 0.8 % methylcellulose . P210 was measured by flow cytomety RESULTS: K562 cells were treated with Aspo, they still grew in clone state and show antisense sequence specific and dose dependent. When the concentration of Aspo was more than Spznol/L, the growth of cells was inhibited and P210 was down regulated or completely suppressed, and the greatest growth inhibition was at 120h . There was signifi-cant inhibition of cell proliferation in a rang‘cells number from 1×10⁴/mL to 5×10⁴/mL after treatment with 10unol/L Aspo. b2a2 Aspo was also effect on K562 cells which expressing b3a2 mRNA.CONCLUSION: bcr-abl Aspo has a specific growth inhibition effect on K562 cells, and worths further study in CML gene therapy.     

Inhibition of c-Myc by 10058-F4 overcomes imatinib resistance in chronic myeloid leukemia cells

AIM：To investigate the effect of c-Myc inhibitor 10058-F4 on human chronic myeloid leukemia (CML) K562 cells and imatinib-resistant K562/G cells. METHODS：The protein expression of c-Myc was detected by Western blotting. Cell proliferation was evaluated by MTT assay and colony formation assay. PI staining was used to determine the cell cycle distribution. Annexin V-PI staining was applied for apoptosis detection. RESULTS：Imatinib-resistant K562/G cells displayed lower sensitivity to imatinib than K562 cells with high expression of c-Myc. Treatment with specific c-Myc inhibitor 10058-F4 inhibited the cell proliferation in a dose- and time-dependent manner, and K562/G displayed more sensitivity to 10058-F4 than K562 cells. 10058-F4 also induced cell cycle arrest in G0/G1 phase and induced apoptotic cell death in the 2 cells. Importantly, 10058-F4 suppressed the colony formation ability in K562 and K562/G cells. CONCLUSION：c-Myc is a novel target to overcome imatinib-induced drug resistance, and c-Myc inhibitor provides a new approach in CML therapy.     

Changes in TCR Vβ subfamily nave T cells in peripheral blood of patients with multiple myeloma

AIM: To detect the existence of signal joint T-cell receptor excision DNA circles (sjTRECs) of 23 TCR Vβ subfamilies in mononuclear cells of patients with multiple myeloma (MM), and to evaluate the recent thymic emigrants of corresponding Vβ subfamily nave T cells in MM patients. METHODS: 23 TCR Vβ subfamily sjTRECs were amplified in genomic DNA from 5×104 PBMCs of 12 cases in MM patients by using semi-nest PCR.10 normal individuals served as controls. RESULTS: The number of detectable Vβ subfamily sjTRECs was 5.00±2.45 from MM patients, as compared with 9.60±5.48 from normal individuals, the difference was significant (P<0.05). The frequencies of Vβ2-, Vβ10-, Vβ16-, Vβ17-, and Vβ21-Dβ1 sjTRECs were significantly lower than those from normal individuals. 2-9 Vβ subfamily sjTRECs were detected from 12 cases of MM patients. It was negative correlation between age and the number of detectable Vβ subfamily sjTRECs in MM patients (r=-0.892; P<0.01). CONCLUSION: It has been found that some of 23 Vβ subfamily nave T cells are absent or lower level of recent thymic output function in MM patients, suggesting that MM patients have severe cellular immunodeficiency and the capacity and potential of long-term TCR Vβ repertoire reconstitution are dramatically lowered.     

WT1 peptide-loaded DC triggers cytotoxic T lymphocytes and killing effects on K562 cells in vitro

AIM: To study the effects of WT1 peptide-loaded dendritic cells (DC) stimulating the cytotoxic T lymphocytes (CTL) on K562 cells in vitro. METHODS: DC were generated from normal human peripheral blood mononuclear cells (PBMC) in the presence of granulocyte-macrophage colony stimulating factor(GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor alpha (TNF-α) , DC were cultured with WT1 peptides , and then triggered T cells into specific CTL. RESULTS: Most suspended cells exhibited distinctive morphological features of DCs and they stimulated proliferation of allogenic lymphocytes. Under the effector : target ratio of 20∶1, CTLs derived from cultures with DC and WT1 peptides were showed 86.1%±26.8% cytotoxicity against K562 cells, cytotoxicity by CTLs derived from cultures with unloaded DC against K562 cells were 47.1%±20.8% and cytotoxicity by lymphocytes were 27.7%±15.3%. Cytotoxicity by CTLs derived from culture with WT1 peptides-loaded DC were the strongest among three groups （P＜0.05）. CONCLUSION: CTLs derived from cultures containing DC pulsed with WT1 peptides show the strongest cytolytic activities on K562 cells.     

Effect of monocyte/macrophages activated by CpG-oligodeoxynucleotides of bacteria on K562 cells

AIM: To study the effect of monocyte/macrophages treated with CpG-oligodeoxynucleotides on leukemic K562 cells. METHODS: The monocytes/macrophages from peripheral blood cells were isolated and induced. The expressions of CD14 and CD16 on monocytes/macrophages were detected by means of flow cytometry. After treated with synthetic CpG-oligodeoxynucleotides, and nonCpG-oligodeoxynucleotides for 24 hours respectively, the inhibiting effect of monocyte/macrophages on K562 cells were detected using MTT method. The secretions of TNF-α and IL-12 from monocytes/macrophages were determined using ELISA method. RESULTS: The monocytes/macrophages treated with CpG-oligodeoxynucleotides enhanced their antitumor effect on K562 cells and increased the secretion levels of TNF-α and IL-12. Whereas, there was no significant difference between antitumor effect and cytokine secretion of the monocytes/macrophages treated with nonCpG-oligodeoxynucleotide. CONCLUSION: CpG-oligodeoxynucleotides increases the cytotoxicity of macrophages on K562 cells in vitro, as well as facilitates the IL-12 and TNF-α secretion. It provides a new approach for immunologic treatment of leukemia.     

Construction and expression analysis of idiotype TCR Vβ2 DNA vaccine in vitro

AIM:To develop an anti-lymphoblastic leukemia TCR idiotypic DNA vaccine, analyze its transfer activity into K562 cells and to detect its expression in vitro. METHODS:The TCR Vβ2 gene segment, which was identified from an idiotypic TCR Vβ2 clone-Molt4 cell line, was amplified using RT-PCR, and the PCR products were then cloned into pIRES vector. The recombinant plasmids were transferred into K562 cells. The condition of idiotypic protein expression was tested by indirect immunophenotyping fluorescein dyeing, SDS-PAGE and Western blotting. RESULTS:The recombinant DNA plasmid, pIRES-TCR Vβ2, was developed successfully. The expression of TCR Vβ2 was identified on the surface of K562 cells. A 15 kD protein, which bound to TCR Vβ2 antibody specifically, were identified from pIRES-TCR Vβ2 transfected K562 cells by Western blotting, indicating that TCR Vβ2 protein was expressed in vitro. CONCLUSION:The recombinant plasmid pIRES-TCR Vβ2 DNA vaccine was developed successfully, which was expressed TCR Vβ2 protein specifically in transfected K562 cells.     

Antigen-loaded dendritic cells and CD40L triggers the killing effects of cytotoxic T lymphocytes on K562 cells in vitro

AIM:To investigate the anti-tumor effects of special cytotoxic T lymphocytes (CTLs) activated by dendritic cells (DCs) loaded with antigens and CD40L in vitro.METHODS:Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation from normal human heparinized blood.The adherent cells were cultured with granulocyte-macrophage colony stimulating factor (GM-CSF),interleukin-4 (IL-4),alpha tumor necrosis factor (TNF-α),DCs were co-cultured with frozen-thawed antigen of K562 cells and CD40L,then triggered T cells into specific CTLs.RESULTS:Most suspended cells exhibited distinctive morphological features of DCs which expressed CD40 96%,CD86 97%,CD80 77%,CD1a 69%,and gained the powerful capacity to stimulate proliferation of allogenic lymphocytes.Under the effector∶target ratio of 20∶1,CTLs derived from cultures with DCs and frozen-thawed antigen of K562 cells were showed 71.3% cytotoxicities against K562 cells.CTLs derived from cultures with DCs loaded with frozen-thawed antigen and CD40L were showed 86.9% cytotoxicities against K562 cells.Cytotoxicities by CTLs derived from cultures with unloaded DCs against K562 cells were 37.6% and cytotoxicities by monocytes were 21.1%.Cytotoxicities by CTLs derived from experiment groups were stronger than control groups (P<0.05).CONCLUSIONS:The tumor antigen-pulsed DCs induces efficient and specific anti-tumor immunity,CTLs derived from cultures containing DCs pulsed with CD40L show the strongest cytolytic activities on K562 cells.     

The feature of TCR-zeta chain expression in patients with CML by real-time quantitative PCR

AIM: To establish a real-time PCR technique for detection and quantification of TCR ζ chain expression and to investigate TCR ζ chain expression level in patients with chronic myeloid leukemia (CML). METHODS: Real-time PCR with SYBR GreenⅠ technology was used for detecting TCR ζ chain expression level in peripheral blood mononuclear cells from 30 patients with CML and 30 normal individuals. β2 -microglobulin gene (β2M) was used as an endogenous reference. Relative changes in TCR ζ chain expression level were used by the 2- △△Ct method between patients with CML and normal individuals. RESULTS: The SYBR GreenⅠ real-time technique for quantitative detection of TCR ζ chain expression levels was established successfully. The expression level of TCR ζ chain in 18 patients with CML was reduced. However, the TCR ζ chain expressed increased in 12 patients with CML. CONCLUSION: The TCR ζ chain expression level is divided into down expression (60%) and over expression (40%) groups, and the down expression of TCR ζ chain might related to cellular immunodeficiency in most of CML patients.     

MicroRNA-3666 regulates expression of phosphatase and tensin homologue deleted on chromosome ten in leukemic cells

AIM: To explore the regulatory effect of microRNA-3666 (miR-3666) on the expression of its target gene phosphatase and tensin homologue deleted on chromosome ten (PTEN) in leukemic cells. METHODS: miR-3666 expression levels in normal peripheral blood mononuclear cells and leukemic cells were determined by quantitative real-time PCR. miR-3666 targeting PTEN 3-untranslated region (3UTR) was predicted by TargetScan software. 3UTR of PTEN was inserted in the dual luciferase reporter vector psiCHECK2. The reporter activity was evaluated by the Dual-Luciferase Reporter Assay System after the luciferase promoter vector and miRNA were co-transfected into HEK293T cell line. K562 cells were transfected with synthetic miR-3666 inhibitor (anti-miR-3666) or a synthetic control miRNA (anti-miR-C). The expression of PTEN protein in the above transfected K562 cells was determined by Western blotting. RESULTS: miR-3666 was up-regulated in the human leukemic cell lines and primary leukemic cells compared to normal peripheral blood mononuclear cells. The results of dual luciferase assays validated PTEN as a specific target gene of miR-3666. Inhibition of miR-3666 resulted in an up-regulation of PTEN protein expression in the K562 cells. CONCLUSION: miR-3666 is over-expressed in leukemic cells. The abnormal over-expression of miR-3666 may play a key role in leukemia due to the down-regulation of PTEN.     

Knockdown of RALA by siRNA inhibits cell proliferation and induces apoptosis in human leukemic K562 cells

AIM: To investigate the effect of siRNA-induced knockdown of v-ral simian leukemia viral oncogene homolog A(RALA) on proliferation and apoptosis of chronic myelogenous leukemia(CML) K562 cells. METHODS: The chemically synthesized siRNA targeting to RALA gene was transfected into K562 cells using Lipofectamine^TM 2000. The proliferation and viability of K562 cells were detected by MTT assay and trypan blue dye exclusion. The expression levels of RALA mRNA and protein were determined by quantitative real-time PCR and Western blotting,respectively. The cell apoptosis was analyzed using flow cytometry by double staining with annexin V and propidium iodide, and the apoptotic morphological changes were detected by Hoechst 33258 staining. RESULTS: RALA siRNA significantly down-regulated RALA mRNA and protein expression in K562 cells(P<0.05). The proliferation of K562 cells in RALA siRNA group was inhibited compared with control group(P<0.05). The apoptotic rate was much higher in RALA siRNA group than that in negative control group(P<0.05). The apoptotic morphological changes were observed in the nuclei of K562 cells transfected with RALA siRNA. CONCLUSION: The siRNA-mediated knockdown of RALA results in inhibition of proliferation and induction of apoptosis in K562 cells, indicating that RALA might be used as a potential therapeutic target in chronic myelogenous leukemia.     

Establishment of T-lymphocytes that express CD20scFv-IgGFc-CD28-ζ and CD20scFv-IgGFc and their killing activity of B-lymphoma cells

AIM: To investigate the target killing effect of T lymphocytes with chimeric CD20scFv gene on Daudi cells and the activation of T lymphocytes. METHODS: Two kinds of plasmids were transfected into retrovirus-packed PA317 cell lines. The supernatant was collected from successfully transfected PA317 culture and was used to infect peripheral blood T lymphocytes. After one-week screening with G418, the cells were used to kill Daudi and K562 cells. The positive rates of AnnexinⅤ in Daudi cells were measured at different times points respectively by flow cytometry. Meanwhile, the level of IL-2 and IFN-γ were determined by ELISA. RESULTS: The Annexin V positive rate was significant higher in Daudi cells compared to control K562 cell lines at 24 h. No difference of AnnexinV in Daudi cells was observed in CD20 modification T lymphocyte groups. The secretions of IL-2 and IFN-γ in CD20scFv-CD80-IgGFc-CD28-ζ gene modified T cells co-cultured with Daudi cells were dramatically higher than that in CD20scFv-IgGFc group at 72 h. CONCLUSION: ① The two kinds of genetic modified specific T cells have no significant difference in inducing early apoptosis of Daudi cells. CD28-ζ cant affect Daudi cell early apoptosis at the CD20scFv target killing. ② The increase in the secretions of IL-2 and IFN-γ is more obvious in CD20scFv-IgGFc-CD28-ζ group, indicating that the self-activation takes place in CD3ζ and CD28 modified T cells without MHC restriction and then increases the activation and killing function of T cells.